Trevi Therapeutics, Inc.(NASDAQ : TRVI)
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
Health Technology » Pharmaceuticals Major
|MRK||Merck & Co., Inc.||2.35%||78.97||0.7%||$1568.32m|
|JNJ||Johnson & Johnson||2.99%||164.90||0.7%||$1006.99m|
|BMY||Bristol-Myers Squibb Co.||0.94%||57.48||1.0%||$657.54m|
|LLY||Eli Lilly & Co.||0.96%||241.28||1.1%||$615.22m|
|NVO||Novo Nordisk A/S||1.33%||104.80||0.1%||$91.83m|
|EDSA||Edesa Biotech, Inc.||5.81%||8.19||0.0%||$74.98m|
|CRVS||Corvus Pharmaceuticals, Inc.||2.60%||4.74||0.7%||$57.97m|
Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization Haduvio to treat serious neurologically mediated conditions. It includes treatment of chronic pruritus associated with prurigo nodularis and chronic cough in patients with idiopathic pulmonary fibrosis, and levodopa-induced dyskinesia in patients with Parkinsonâ€™s disease. The company was founded by Thomas R. Sciascia and Jennifer L. Good in March 2011 and is headquartered in New Haven, CT.